Everolimus for the prevention of organ rejection in kidney transplantation
For information everolimus was considered within the MTA for Kidney transplantation (adults) - immunosuppressive therapy (ID456), rather than being appraised as a separate STA. This MTA has now published as TA481
 
Status Discontinued
Decision Selected
Process TA
Referral date 01 July 2009
Topic area
  • Urogenital

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC

Timeline

Key events during the development of the guidance:

Date Update
01 November 2017 Discontinued. For information everolimus was considered within the MTA for Kidney transplantation (adults) - immunosuppressive therapy (ID456), rather than being appraised as a separate STA. This MTA has now published as TA481

For further information on our processes and methods, please see our CHTE processes and methods manual